Learning and Executive Function Disorders in Children and Psychosis Risk at Adult-age
NCT ID: NCT04280367
Last Updated: 2023-08-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
20 participants
OBSERVATIONAL
2020-01-28
2020-05-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dimensional and Developmental Profiles of Psychosis in Children and Adolescents
NCT04370730
Prevalence of Dissociative Disorders in Children
NCT01512641
Study of the Impact on the Therapeutic Alliance of a Short Initial Psychoeducation Programme in Patients With Early Schizophrenia
NCT04867681
Discriminant Validity of the Multiple Errands Test in Schizophrenia
NCT02782091
Group Psychoeducation to Promote Independent Living in Individuals With Psychiatric Disorders
NCT07317388
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* argue the clinical predicted markers (neuropsychological) transition toward psychosis.
* test the feasibility and the acceptability of a early diagnosis for a potential applicable guidance for different referent centers of learning in French territory.
* have a better classification of patients with learning disorders in order to target a prospective primary prevention of risk of psychosis via the questionnaires (AQ of Baron-Cohen: Autism-spectrum quotient auto-questionnaire; Inventory of Beck Anxiety Inventory, auto-questionnaire for panic disorder and general anxiety; Liebowitz Social Anxiety Scale).
* improve identification of the early signs and the early emerging psychological diseases intervention management (schizophrenia).
* Psychic disability: prevent and reduce non-seeking care and accompaniment situations, and risk of rupture of care.
* permitting better care of psychosocial rehabilitation with cognitive evaluation.
This study will be conducted in Centre de référence des troubles du langage et des apprentissages, Hôpital Raymond Poincaré, APHP, in France.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Comparator group
Specific learning disorders group
Standardised semi-structured talk
Comprehensive assessment of at-risk mental states (CAARMS) will be used.
Autistic spectre disorder screening
Autism-spectrum quotient (AQ) auto-questionnaire will be used.
Anxiety measuring
An inventory for measuring clinical anxiety: Beck Anxiety Inventory (BAI); Liebowitz Social Anxiety Scale.
neuro-developmental complexed group
Group of neuro-developmental complexe of learning
Standardised semi-structured talk
Comprehensive assessment of at-risk mental states (CAARMS) will be used.
Autistic spectre disorder screening
Autism-spectrum quotient (AQ) auto-questionnaire will be used.
Anxiety measuring
An inventory for measuring clinical anxiety: Beck Anxiety Inventory (BAI); Liebowitz Social Anxiety Scale.
Complexed with anxiety
Disorders in learning with anxiety
Standardised semi-structured talk
Comprehensive assessment of at-risk mental states (CAARMS) will be used.
Autistic spectre disorder screening
Autism-spectrum quotient (AQ) auto-questionnaire will be used.
Anxiety measuring
An inventory for measuring clinical anxiety: Beck Anxiety Inventory (BAI); Liebowitz Social Anxiety Scale.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Standardised semi-structured talk
Comprehensive assessment of at-risk mental states (CAARMS) will be used.
Autistic spectre disorder screening
Autism-spectrum quotient (AQ) auto-questionnaire will be used.
Anxiety measuring
An inventory for measuring clinical anxiety: Beck Anxiety Inventory (BAI); Liebowitz Social Anxiety Scale.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* With severe learning disorders: deficiency in school work, need at least one medical appointment and long-term rehabilitation in the center of language and learning disorders at Raymond Poincaré hospital;
* Affiliated to a social protection schema;
* Written informed consent signed.
Exclusion Criteria
* Intellectual deficiency;
* Epilepsia;
* Patients who will performed follow-up at Chartres city;
* Patients under guardianship or curatorship;
* Foreign patients under AME schema, a medical help from the state in France.
15 Years
30 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emilie SCHLUMBERGER, MD
Role: PRINCIPAL_INVESTIGATOR
Centre de référence des troubles du langage et des apprentissages, Hôpital Raymond Poincaré, APHP
Albane Mansoux
Role: STUDY_DIRECTOR
Centre de référence des troubles du langage et des apprentissages, Hôpital Raymond Poincaré, APHP
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre de référence des troubles du langage et des apprentissages, Hôpital Raymond Poincaré
Garches, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-A02663-54
Identifier Type: REGISTRY
Identifier Source: secondary_id
APHP191093
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.